All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The completion of the third largest biopharmaceutical acquisition on record has significantly boosted M&A values in 2021, although the industry still falls more than 38% below the same period last year.
Bioworld’s Drug Developers Index is at its highest point this year, up 4.99%, despite some index members receiving FDA complete response letters and reporting lower-than-expected sales within the last month. Moderna Inc., with its mRNA-1273 COVID-19 vaccine gaining more traction worldwide, is largely responsible for the rise, with its own shares (NASDAQ:MRNA) up nearly 285%.
Clinical data in 2021 has risen by about 9.2% in comparison with the same timeframe in 2020. As of mid-August, BioWorld has tracked a total of 2,400 entries of clinical data, which is up from the 2,197 entries last year. The gap has decreased from about 26% in mid-April, suggesting a steady slowdown in activity.
RSS
